Current Report Filing (8-k)
August 11 2016 - 3:07PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
August 11, 2016
Applied
DNA Sciences, Inc.
(Exact name of registrant as specified in its
charter)
Delaware
(State or other jurisdiction
of incorporation)
|
001-36745
(Commission File Number)
|
59-2262718
(IRS Employer
Identification No.)
|
50 Health Sciences Drive
Stony Brook, New York 11790
(Address of principal executive offices; zip
code)
Registrant’s telephone number, including
area code:
631-240-8800
N/A
(Former name or former address, if changed since
last report)
Check the appropriate box below if the Form
8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
¨
|
Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 2.02 Results of Operations and Financial Condition.
On August 11, 2016, Applied DNA Sciences, Inc. (“Applied
DNA Sciences” or the “Company”) issued a press release announcing its results of operations for the fiscal quarter
ended June 30, 2016. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information furnished pursuant to this Item 2.02, including
Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended
(the “Exchange Act”), or otherwise subject to the liabilities under that Section and shall not be deemed to be incorporated
by reference into any filing of the Company under the Securities Act of 1933 or the Exchange Act, except as shall be expressly
set forth by specific reference in such filing.
Item 9.01. Financial Statements and Exhibits.
(
d) Exhibits
|
99.1
|
Press Release of Applied DNA Sciences, Inc. dated August 11, 2016 regarding results of
operations for the fiscal quarter ended June 30, 2016.
|
SIGNATURE
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
Date: August 11, 2016
|
APPLIED DNA SCIENCES, INC.
|
|
|
|
|
By:
|
/s/ James A. Hayward
|
|
Name:
|
James A. Hayward
|
|
Title:
|
Chief Executive Officer
|
EXHIBIT INDEX
Exhibit No.
|
|
Description
|
99.1
|
|
Press Release issued by Applied DNA Sciences, Inc. dated
August 11, 2016 regarding results of operations for the fiscal quarter ended June 30, 2016.
|
Applied DNA Sciences (NASDAQ:APDN)
Historical Stock Chart
From Apr 2024 to May 2024
Applied DNA Sciences (NASDAQ:APDN)
Historical Stock Chart
From May 2023 to May 2024